Toni Luise Meister

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1898725/publications.pdf

Version: 2024-02-01

471371 434063 1,122 36 17 31 citations h-index g-index papers 42 42 42 2140 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2. Journal of Hospital Infection, 2022, 120, 9-13.	1.4	12
2	Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. Frontiers in Immunology, 2022, 13, 816220.	2.2	22
3	A Vector-Based Vaccine Dose After 3 Doses of mRNA-Based COVID-19 Vaccination Does Not Substantially Improve Humoral SARS-CoV-2 Immunity in Renal Transplant Recipients. Kidney International Reports, 2022, 7, 932-934.	0.4	5
4	Differential interferon- $\hat{l}\pm$ subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	33
5	Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses. Kidney International, 2022, 101, 1287-1289.	2.6	16
6	A touch transfer assay to determine surface transmission of highly pathogenic viruses. STAR Protocols, 2022, 3, 101188.	0.5	0
7	Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients. Journal of Infectious Diseases, 2022, 226, 1608-1615.	1.9	12
8	Nanoscale copper and silver thin film systems display differences in antiviral and antibacterial properties. Scientific Reports, 2022, 12, 7193.	1.6	29
9	Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial. Virus Research, 2022, 316, 198791.	1.1	18
10	Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses. Kidney International, 2022, 102, 207-208.	2.6	12
11	Pasteurization Inactivates SARS-CoV-2–Spiked Breast Milk. Pediatrics, 2021, 147, .	1.0	18
12	The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression. Transplantation, 2021, 105, 2156-2164.	0.5	31
13	Disinfection of SARS-CoV-2 Contaminated Surfaces of Personal Items with UVC-LED Disinfection Boxes. Viruses, 2021, 13, 598.	1.5	23
14	Detection of SARSâ€CoVâ€2â€specific memory B cells to delineate longâ€term COVIDâ€19 immunity. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2595-2599.	2.7	7
15	Comparable Environmental Stability and Disinfection Profiles of the Currently Circulating SARS-CoV-2 Variants of Concern B.1.1.7 and B.1.351. Journal of Infectious Diseases, 2021, 224, 420-424.	1.9	35
16	Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. Journal of Nephrology, 2021, 34, 1025-1037.	0.9	6
17	Antiviral Effect of Budesonide against SARS-CoV-2. Viruses, 2021, 13, 1411.	1.5	13
18	A realistic transfer method reveals low risk of SARS-CoV-2 transmission via contaminated euro coins and banknotes. IScience, 2021, 24, 102908.	1.9	21

#	Article	IF	Citations
19	The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. Virus Research, 2021, 302, 198469.	1.1	28
20	A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse. Kidney International, 2021, 100, 1135-1136.	2.6	38
21	Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients. Kidney International, 2021, 100, 698-700.	2.6	8
22	Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease. Kidney International, 2021, 100, 1335-1337.	2.6	11
23	Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2. Journal of the American Society of Nephrology: JASN, 2021, 32, 2725-2727.	3.0	15
24	Reply to Lamarca et al. Journal of Infectious Diseases, 2021, 223, 1114-1115.	1.9	0
25	Robust hepatitis E virus infection and transcriptional response in human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1731-1741.	3.3	67
26	Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. Cell Reports Medicine, 2020, 1, 100092.	3.3	148
27	Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines, 2020, 8, 386.	2.1	75
28	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a++. Molecular Therapy, 2020, 28, 2691-2702.	3.7	35
29	Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2020, 222, 1289-1292.	1.9	146
30	Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient. American Journal of Transplantation, 2020, 20, 3210-3215.	2.6	19
31	A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks. Journal of Visualized Experiments, 2020, , .	0.2	4
32	Characterization of Equine Parvovirus in Thoroughbred Breeding Horses from Germany. Viruses, 2019, 11, 965.	1.5	24
33	Equine Parvovirus-Hepatitis Frequently Detectable in Commercial Equine Serum Pools. Viruses, 2019, 11, 461.	1.5	20
34	Cell culture systems for the study of hepatitis E virus. Antiviral Research, 2019, 163, 34-49.	1.9	60
35	Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse. Current Opinion in Virology, 2018, 32, 80-87.	2.6	49
36	Impact of low eGFR on the immune response against COVID-19. Journal of Nephrology, 0, , .	0.9	0